The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with [...]
Is European market access really so difficult? Tell us the truth about being successful in Europe, Esther Nzenza!
Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country [...]
What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability [...]
Podcast Q&A: Cracking the Code: When and How to Validate ICD Algorithms for RWE
This podcast segment features the Q&A from PHAR LLC's webinar from April 12, 2022 which featured experts from PHAR, Genentech, [...]
Podcast Q&A: Optimizing Real-World Evidence for Maternal and Neonatal Outcomes
This podcast segment features the Q&A from HealthCore's webinar from April 9, 2022 which featured an expert panel of health [...]
Digital Health Care is already fully utilized in the US, isn’t it?
Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in [...]
Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the [...]
Podcast Q&A: How Literature Review Automation and Efficient Processes Streamline RWE HEOR Studies?
This podcast segment features the Q&A from Evidence Partners' webinar from March 9, 2022. This webinar, moderated by Dr. Patti [...]
What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system. The [...]
The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of [...]
How can a company derive the optimal price for their medical product, Dr. Renato, Dellamano?
What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How [...]
How do innovations reach patients in German hospitals, Dr. Sebastian Casu?
How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are [...]
How does hospital funding work in Germany, Willi Wöllner?
How does reimbursement work in the German hospital setting and how are hospitals organized doing such negotiations? What is a NUB and [...]
Prof. Dr. Juergen Wasem – What happens, when negotiations fail?
Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the [...]
Dr. Michael Zuercher – Commerical attractiveness of the Swiss health care market – success starts with market access.
In this Podcast episode Dr. Stefan Walzer confronts the Swiss expert Michael Zuercher with his perspective on Market Access to [...]
Prof. Peter Zweifel & Door Vonk – Digital Innovation – from theory into practice!
In this Podcast episode, Dr. Stefan Walzer is discussing innovation theory from an economics perspective together with Prof. Peter Zweifel [...]
Bibiane Schulte-Bosse – How to fight well in AMNOG negotiations.
In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together [...]
Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier – 1 year DIGAs. Is the “fast track process” for digital health applications successful?
In this Podcast episode, Dr. Stefan Walzer is reflecting on 1 year DIGAs with the leading question whether the "fast [...]
Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including [...]
Prof. Dr. Wagschal – What can we expect from the upcoming elections in Germany?
In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the [...]
Dr. Mathias Flume – AMNOG will change in 2022, but how?
In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as [...]
